INFO 1:
Brussels (BELGIUM), October 26, 2007 at 7:00 am CET - Phase III clinical trials of UCB's antiepileptic drug (AED) in development, brivaracetam , are underway, as adjunctive therapy in patients with refractory partial-onset epilepsy. Rikelta(TM) is the proposed tradename for brivaracetam . 25/10/07 22:10:00 | 2695
-------------------------------------------------------------------------------------------------------------------------------------------
INFO 2:
UCB announces first results from Phase III brivaracetam studies in epilepsy
- One study met its primary efficacy endpoint while the second study did not meet its primary efficacy endpoint
- A third safety and tolerability study confirmed brivaracetam was well tolerated
- Further analysis will be conducted and regulatory authorities will be consulted to determine next steps to bring brivaracetam to patients
Brussels (Belgium), 28 April 2009 - 07:00 am (CEST) -
press release, regulated information - UCB announced today top-line results from two Phase III clinical studies to assess the efficacy and safety of
brivaracetam as adjunctive treatment of partial-onset seizures in adults with epilepsy. Results were also announced for a third well-controlled safety and tolerability study.
SOURCE:
http://www.ucb.com/presscenter/News...om-Phase-III-brivaracetam-studies-in-epilepsy
reading this information I carefully conclude 2 things.
1. it takes YEARS for these drugs to come to the patients. They were speaking about phase 3 in 2007 and 2009. We are 6 years later.
2. The double blind controlled study started with milligrams in the range of nr`s like 5-50 ... I think the end nr was 200 mg daily. This makes me believe that Autifony also might start very low and therefor we have n`t yet heard of or maybe won`t hear of any positive effects soon. On the other hand it still gives hope that if they find the sweetspot it might be that AUT00063 is the drug we all been waiting for.
I sent UCB an email today and asked to speak to one of their people considering a few topics. I will keep you informed.
EDIT: Anyone have a good question I can ask please shoot ...